Viral protease inhibitors
Department of Biochemistry and Molecular Pharmacology
Animals; Antiviral Agents; Cysteine Endopeptidases; Cytomegalovirus; Drug Resistance, Viral; Drug Therapy, Combination; HIV Protease Inhibitors; Hepacivirus; Humans; Models, Molecular; Peptide Hydrolases; Protease Inhibitors; SARS Virus; Viral Nonstructural Proteins; Viral Proteins; Viruses
Biochemistry, Biophysics, and Structural Biology | Microbiology
This review provides an overview of the development of viral protease inhibitors as antiviral drugs. We concentrate on HIV-1 protease inhibitors, as these have made the most significant advances in the recent past. Thus, we discuss the biochemistry of HIV-1 protease, inhibitor development, clinical use of inhibitors, and evolution of resistance. Since many different viruses encode essential proteases, it is possible to envision the development of a potent protease inhibitor for other viruses if the processing site sequence and the catalytic mechanism are known. At this time, interest in developing inhibitors is limited to viruses that cause chronic disease, viruses that have the potential to cause large-scale epidemics, or viruses that are sufficiently ubiquitous that treating an acute infection would be beneficial even if the infection was ultimately self-limiting. Protease inhibitor development is most advanced for hepatitis C virus (HCV), and we also provide a review of HCV NS3/4A serine protease inhibitor development, including combination therapy and resistance. Finally, we discuss other viral proteases as potential drug targets, including those from Dengue virus, cytomegalovirus, rhinovirus, and coronavirus.
DOI of Published Version
Handb Exp Pharmacol. 2009;(189):85-110. Link to article on publisher's site
Handbook of experimental pharmacology
Anderson, Jeffrey; Schiffer, Celia A.; Lee, Sook-Kyung; and Swanstrom, Ronald I., "Viral protease inhibitors" (2009). Biochemistry and Molecular Pharmacology Publications and Presentations. 144.